Trial · NCT04611139
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
NCT04611139, Phase 1, Withdrawn, HonorHealth Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers. Trials, record NCT04611139. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04611139
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
- NCT number
- NCT04611139
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- HonorHealth Research Institute
- Conditions
- SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer
- Interventions
- SP-2577, Pembrolizumab
- First posted
- 2020-11-02
- Last updated
- 2022-03-02
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incident of AEs | First dose to 90 days after last dose | Incidence of Adverse Events (AEs) as measured by NCI CTCAE version 5.0 |
| Primary | Incident of DLTs | First dose to 90 days after last dose | Incidence of dose-limiting toxicities (DLTs) during the dose escalation phase |
| Primary | Overall Response Rate | Study enrollment until participant discontinuation, occurrence of PD or death (approximately 6 months to 3 years) | Percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR), as determined by Investigator according to Response Evaluation in Solid Tumors (RECIST) v 1.1 |
| Primary | Disease Control Rate | Study enrollment until PD or loss of clinical benefit (approximately 6 months to 3 years) | Percentage of participants with Disease Control (complete response, partial response, or stable disease) as determined by RECIST v1.1 |
| Primary | Duration of Response | Date of first occurrence of objective response to first documentation of PD (approximately 6 months to 3 years) | Duration of Response as determined by the Investigator according to RECIST v1.1 |
| Primary | Duration of Stable Disease | Date of first occurrence of stable disease to first documentation of PD (approximately 6 months to 3 years) | Duration of Stable Disease as determined by the investigator according to RECIST v 1.1 |
| Primary | Progression Free Survival | Start of treatment to first occurrence of PD or death (approximately 6 months to 3 years) | Progression Free Survival (PFS) as determined by the Investigator according to RECIST v1.1 |
| Primary | Overall Survival | Start of treatment to death (approximately 2 to 3 years) | Overall Survival (OS) as determined by the Investigator according to RECIST v1.1 |
| Secondary | Plasma Concentration of SP-2577 | 2 months | Plasma concentration of seclidemstat (SP-2577) |
| Secondary | ctDNA in blood and other body fluids | 6 months to 2 years | Proportion of circulating tumor DNA ( ctDNA) in peripheral blood and other body fluids e.g. ascitic fluid |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04611139
GET https://conductscience.org/api/trials/v1/NCT04611139/registered